Wings Over Wall Street marks 25 years of ALS fundraising on June 25
The Muscular Dystrophy Association (MDA) will celebrate the 25th anniversary on June 25 of its Wings Over Wall…
Articles by Lindsey Shapiro, PhD
Brainstorm seeking FDA’s OK to launch NurOwn Phase 3b trial
Brainstorm Cell Therapeutics is moving forward in its efforts to get needed regulatory clearances to launch a Phase 3b clinical…
Trace plans ALS trial of UNC13A treatment with help from AI tools
Trace Neuroscience plans to test genomic medicine that targets the UNC13A protein in people with amyotrophic lateral sclerosis…
NUZ-001 slows decline in ALS lung function, Phase 1 trial shows
NUZ-001, which was previously known as monepantel, slowed lung function declines by nearly 50% in people with amyotrophic lateral…
Study highlights role of natural killer immune cell subsets in ALS
Certain subsets of natural killer (NK) cells, a part of the immune system, were elevated in the blood of people…
MDA 2025: Cholesterol receptor ‘critical’ in sporadic ALS disease
Signaling at the low-density lipoprotein receptor, known as LDLR, may be an important driver of neurodegeneration in sporadic amyotrophic…
MDA 2025: INS1202 gene therapy shows promise in SOD1-ALS mice
A single dose of Insmed’s investigational gene therapy INS1202 preserved motor function and prolonged survival in a mouse model…
New HEALEY trial analyses further show CNM-Au8’s survival benefits
Treatment with CNM-Au8 in the HEALEY ALS platform trial prolonged survival for people with amyotrophic lateral sclerosis (ALS)…
Focus of NORD study: Rare disease community’s lived experiences
The National Organization for Rare Disorders (NORD) is seeking participants for its survey-based study Living Rare, which aims to…
Qalsody approved in Canada for ALS tied to SOD1 mutations
Health Canada has conditionally approved Qalsody (tofersen) for the treatment of adults with amyotrophic lateral sclerosis (ALS) associated…